To include your compound in the COVID-19 Resource Center, submit it here.

Otonomy's Meniere’s disease candidate misses in Phase III

Otonomy Inc. (NASDAQ:OTIC) reported data from the double-blind, U.S. Phase III AVERTS-1 trial in 165 patients with unilateral Meniere’s disease who were

Read the full 225 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE